Kyn Therapeutics

Kyn Therapeutics aims to disrupt immunosuppressive metabolic pathways and stimulate an anti-tumor immune response, potentially enhancing the effects of other cancer immunotherapies. Kyn is developing a clinical-stage EP4 antagonist as well as two candidates targeting the highly characterized IDO/TDO/kynurenine pathway.

Headquarters Cambridge, MA
Pipeline Clinical
Twitter @KynTherapeutics​
Partners Celgene